Bristol-Myers Squibb will now challenge its rival, MSD's Keytruda, in second line lung cancer treatment in England after it agreed a 'managed access' deal with NICE.
The charity Cancer Research UK has joined with Biotecnol to begin early-stage clinical trials of a new kind of cancer immunotherapy in solid tumours, including lung cancers.
